OSIRIS THERAPEUTICS (NASDAQ:OSIR)
6.52
0.02 (0.31%)
| OSIRIS THERAPEUTICS (NASDAQ:OSIR) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $6.54 | 52 Week High | $21.65 | ||
| Open | $6.50 | 52 Week Low | $5.35 | ||
| Day High | $6.54 | P/E | N/A | ||
| Day Low | $6.45 | EPS | $-1.08 | ||
| Volume | 33,856 | ||||
| More OSIR Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| HLCS | 3 | NUVA | 3 |
| KHD | 2 | ATHR | 2 |
| ORH | 2 | CBY | 2 |
| SPPI | 2 | SNX | 2 |
| FFH | 2 | ESLR | 2 |
| GTN | 2 | SFE | 2 |
Entities who have mentioned OSIR
- Credit Suisse | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- UBS | View Related Stories »
- JPMorgan | View Related Stories »
- Piper Jaffray | View Related Stories »
- Jefferies & Co | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Morgan Joseph | View Related Stories »
- SunTrust Robinson Humphrey | View Related Stories »
- Barack Obama | View Related Stories »
- Wedbush Morgan | View Related Stories »
- Goldman Sachs Conviction Buy List | View Related Stories »
- JMP Securities | View Related Stories »
- Goldman Sachs Conviction Sell List | View Related Stories »
- ADP Employment Report | View Related Stories »
- Goldman Sachs | View Related Stories »
- Federal Open Market Committee | View Related Stories »
- Collins Stewart | View Related Stories »
- Crude Oil | View Related Stories »
- Cowen & Co | View Related Stories »
- Trading Radar | View Related Stories »
- Dividend | View Related Stories »
- Layoffs | View Related Stories »
- Vanguard | View Related Stories »
- Bankruptcy | View Related Stories »
StreetInsider.com Major News for OSIR
View All ReportsStreetInsider.com Reports on OSIR
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Osiris Therapeutics (OSIR) Achieves $15M Milestone Payment Related to Osteocel Business Sale
- Wedbush Morgan Maintains an 'Outperform' on Osiris Therapeutics (OSIR); Slashes Price Target
- Unusual 11 Mid-Day Movers 9/8: OPXA, ITLN, CBY, ORH Higher; OSIR, UBSH, EXXI, SPPI Lower
- Piper Jaffray Downgrades Osiris Therapeutics (OSIR) to Neutral; Disappointing Top-Line Data From Phase III Trials
View All Press ReleasesCompany Press Releases on OSIR
- Osiris Therapeutics Reports Third Quarter 2009 Financial Results
- Osiris Therapeutics Achieves $15 Million Milestone Payment
- Integrity Media: Stem Cell Report Released
- Osiris Therapeutics Announces Third Quarter 2009 Financial Results Conference Call
- Osiris Therapeutics to Present at Fourth Annual JMP Securities Healthcare Focus Conference
StreetInsider Reports on OSIR by Category
View All BlogsBlogs on OSIR
- Expiration Trade Behind Osiris Activity
- Tuesday Options Recap
- Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
- Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
- Closing Update: Stocks String Together 3 Straight Wins, Commodities Gain
Comments on recent OSIR articles
Comments on OSIR
No comments are currently available.
on Aug 3, 2008
at 10:58 AM Osiris I am pretty close to this company and see no justification for this downgrade. In fact as far as I can see Osiris has acomplished an amazing amount in the past year+. I might also remind investors that if the Graft vs Host indication recieves FDA approval and if the the Chron's indication is accepted many doctors will not wait for the FDA approval in the other indications.
Article: Jefferies & Co Downgrades Osiris Therapeutics (OSIR) to Underperform